M&A | Partnerships

The group purchasing agreement for Synthetic Implantable Products allows Premier members to access pricing and terms for CERAMENT bone void filler.

Kuros has signed a sales agency agreement with various entities, covering the Netherlands, Switzerland, Austria and Finland.

The transaction includes GUIDOR bone graft substitutes known as easy-graft and calc-i-oss, and builds on the company's strategy to expand its technologies.

Over 25,000 of Theracell's licensed demineralized bone fiber products have been delivered by the company's licensee partners.

The expanded agreement with Australian Biotechnologies includes exclusive rights to market demineralized fiber grafts for Australia and New Zealand.

The company and its partners formed TrueBone3D to develop biologically active, patient-tailored bioresorbable implants enriched with ALLOB.

OssDsign expects to see revenue from Osteo3 ZP bone graft substitute putty during 2H21 following approval processes in U.S. hospitals.

Bone Therapeutics granted an exclusive license to develop and collaborate on ALLOB in Greater China and a number of other major Asian countries.

Eisai and Seikagaku will co-develop and market the SI-613 sodium hyaluronate therapeutic agent in South Korea for the treatment of knee osteoarthritis.

Fibrinet enables safe and rapid preparation of Platelet-Rich Fibrin Membrane and Platelet-Rich Fibrin Gel from a small sample of blood at the point of care.